Related Experiment Video
Updated: Apr 28, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
13.6K
Clinical trials in pulmonary hypertension
1University of Colorado Health Sciences Center, Denver 80262, USA. David.Badesch@uchsc.edu
Annual Review of Medicine
|January 1, 1997
Summary
Formal clinical trials are crucial for advancing pulmonary hypertension treatment. Rigorous, multi-center studies are now needed to confirm the safety and efficacy of new therapies.
Area of Science:
- Cardiology
- Pulmonology
- Clinical Trials
Background:
- Treatment progress for pulmonary hypertension has been historically limited by a lack of formal clinical trials.
- The field is now shifting towards more rigorous evaluation of therapeutic strategies.
Purpose of the Study:
- To highlight the critical need for formal clinical trials in pulmonary hypertension research.
- To emphasize the importance of multi-center, randomized controlled trials for assessing treatment safety and efficacy.
Main Methods:
- Review of the current landscape of pulmonary hypertension treatment research.
- Advocacy for the implementation of robust clinical trial methodologies.
Main Results:
- The absence of formal trials has hindered therapeutic advancements.
- A growing recognition of the necessity for evidence-based treatment validation.
Conclusions:
- Randomized, controlled, multi-center trials are essential for evaluating new pulmonary hypertension treatments.
- Promising pilot study results require validation through larger, more rigorous studies.
More Related Videos
Related Concept Videos
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:30Pulmonary Hypertension: Classification and Pathogenesis
904
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
904
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
614
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
614
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689